Completed NA INTERVENTIONAL NCT00015548

CATIE-Alzheimer's Disease Trial

Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)

Sponsor: National Institute of Mental Health (NIMH)

Conditions Alzheimer's Disease

Interventions Citalopram Olanzapine Quetiapine Risperidone

Updated 6 times since 2017 Last updated: Jun 16, 2015 Started: Mar 31, 2001 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00015548, this NA trial focuses on Alzheimer's Disease and remains completed. Sponsored by National Institute of Mental Health (NIMH), it has been updated 6 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Mental Health (NIMH)

Data source: National Institute of Mental Health (NIMH)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Bennington, United States , Boca Raton, United States , Chicago, United States , Coatesville, United States , Dallas, United States , Durham, United States , Hialeah, United States , Honolulu, United States and 22 more locations